Volume | 240,284 |
|
|||||
News | - | ||||||
Day High | 4.75 | Low High |
|||||
Day Low | 4.57 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Inozyme Pharma Inc | INZY | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
4.75 | 4.57 | 4.75 | 4.60 | 4.73 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
3,088 | 240,284 | $ 4.67 | $ 1,121,721 | - | 2.689 - 7.795 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:49:20 | 1 | $ 4.5506 | USD |
Inozyme Pharma Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
284.15M | 61.77M | - | 0 | -71.17M | -1.15 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Inozyme Pharma News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical INZY Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 4.65 | 4.82 | 4.46 | 4.60 | 329,703 | -0.10 | -2.15% |
1 Month | 4.54 | 4.90 | 4.18 | 4.53 | 490,038 | 0.01 | 0.22% |
3 Months | 5.53 | 7.795 | 4.18 | 5.73 | 692,718 | -0.98 | -17.72% |
6 Months | 3.26 | 7.795 | 3.23 | 5.26 | 556,102 | 1.29 | 39.57% |
1 Year | 6.69 | 7.795 | 2.689 | 5.09 | 570,883 | -2.14 | -31.99% |
3 Years | 15.57 | 19.58 | 0.991 | 4.60 | 413,275 | -11.02 | -70.78% |
5 Years | 17.93 | 31.6499 | 0.991 | 5.35 | 339,511 | -13.38 | -74.62% |
Inozyme Pharma Description
Inozyme Pharma Inc is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies. Its product candidate, INZ-701, is a soluble, recombinant, or genetically engineered, fusion protein that is designed to correct a defect in the mineralization pathway caused by ENPP1 and ABCC6 deficiencies. |